Telehealth LTV:CAC Ratio: The Benchmark That Actually Matters

Aim for a telehealth LTV:CAC ratio of 4:1 to 6:1, and treat 3:1 as the minimum healthy floor (illustrative ranges). Below 3:1, acquisition rarely scales; above 6:1, you are probably underinvesting in growth. The number that decides whether a refill-driven clinic compounds is the ratio between lifetime value and acquisition cost, not either figure alone.

Raw CAC tells you what a patient costs. Raw LTV tells you what a patient is worth. Neither, by itself, tells you whether you can pour money into growth without lighting it on fire. The ratio does. And for a compounded-Rx business that lives on monthly refills, one input quietly moves that ratio more than most founders expect: how much of each order value a third party skims before it reaches you.

What is a good LTV:CAC ratio for a telehealth clinic?

For a refill-driven telehealth clinic, target 4:1 to 6:1 and hold 3:1 as the floor (illustrative). At 4:1 to 6:1, each dollar of acquisition returns four to six dollars of contribution over a patient's lifetime, leaving room to fund growth, absorb refunds, and still bank margin. These are conventions, not laws.

The 3:1 rule of thumb comes from software and venture practice, popularized in SaaS metrics writing and repeated across growth teams for more than a decade. It is a heuristic, not a regulatory or scientific threshold. It travels well to telehealth because a subscription-style Rx clinic behaves like a subscription business: acquire once, monetize across many recurring orders.

The ranges and what they mean

The table below reads the ratio as a diagnostic. Values are illustrative interpretations, not measured outcomes.

LTV:CAC ratio	What it usually means	Action
Below 1:1	You lose money on every acquired patient	Stop scaling spend; fix margin or retention first
1:1 to 3:1	You acquire, but the return is thin	Improve refill retention and gross margin before adding budget
3:1 to 4:1	Healthy floor; the model works	Scale acquisition carefully and watch payback
4:1 to 6:1	Strong and sustainable	Invest in growth; this is the target band
Above 6:1	Likely underinvesting in acquisition	Spend more; you are leaving growth on the table

The two failure modes are symmetric. A low ratio means you are buying patients you cannot profitably serve. A very high ratio means you are being too cautious and a faster competitor can outspend you into the same patients. The goal is not to maximize the ratio; it is to keep it in a band where growth is both profitable and aggressive.

Why does the ratio matter more than CAC or LTV alone?

CAC and LTV each answer half a question. A $250 CAC looks alarming next to a $180 lifetime value and reasonable next to an $840 one. The ratio fuses cost and worth into a single scale-readiness signal, which is why growth teams budget against it rather than against either number in isolation.

Consider two clinics. Clinic A has a low $120 CAC but patients churn after two refills, giving a modest lifetime value. Clinic B spends $260 to acquire but retains patients across ten refills. On CAC alone, Clinic A looks disciplined. On the ratio, Clinic B is the stronger business, because its acquisition spend compounds against a much larger lifetime value. Judging on CAC alone would send capital to the weaker book.

Where lifetime value actually comes from

In compounded-Rx categories, lifetime value is a retention story. A patient on a monthly maintenance therapy who refills for ten months is worth roughly five times one who lapses after two. Small movements in refill retention swing lifetime value far more than trimming a few dollars off acquisition creative. That is why subscription-style retention, not the initial sale, is the real engine, a point we develop in more depth on how refill revenue drives lifetime value and in the fuller view of telehealth clinic unit economics.

The practical consequence: if you want to move the ratio, retention and per-order margin are the high-leverage inputs. Anything that erodes per-order margin as refills accumulate works directly against your best growth lever.

What is CAC payback period and how does it fit in?

CAC payback period is the number of months of contribution margin required to earn back the cost of acquiring a patient. It is the cash-flow companion to LTV:CAC. A healthy ratio tells you a patient is worth acquiring; payback tells you how long your cash is tied up before that patient turns net positive.

The two metrics can disagree in ways that matter. A clinic can show a strong 5:1 ratio and still run into a cash wall, because the lifetime value arrives slowly across a year of refills while the acquisition cost is paid up front. For a small clinic without deep reserves, a long payback throttles how fast it can reinvest, regardless of how attractive the lifetime ratio looks on a spreadsheet.

A simple payback read

Using illustrative numbers, take a $200 CAC and a patient who contributes about $84 of margin per month after fees. Payback is roughly 200 divided by 84, or about 2.4 months. Push monthly contribution down to $50 through a heavier fee load and payback stretches to about four months. Same patient, same acquisition spend, but the cash comes back far more slowly, which is exactly where a percentage-based platform fee starts to bite.

How does a revenue-share platform tax compress your ratio?

A revenue-share fee is charged as a percentage of order value, so it recurs on every refill and comes straight out of contribution margin. Because it scales with the same order volume that builds lifetime value, it lowers LTV and the LTV:CAC ratio in lockstep. The healthier your retention, the more absolute value the percentage skims.

This is the core reason to prefer a flat-fee rail over a revenue-share platform. A percentage tax on order value is, functionally, a tax on your lifetime value. It grows precisely as your best patients refill, quietly moving the one benchmark that governs whether you can scale. A flat structure, by contrast, is largely independent of how much each order is worth and how long a patient stays.

A worked comparison, same clinic, two fee models

The scenario below is illustrative and estimated. Both columns describe the identical clinic and identical patient behavior; only the fee model changes.

Line item (illustrative)	Flat-fee rail	Revenue-share platform
Average order value	$200	$200
Orders per patient lifetime	10	10
Gross revenue per patient	$2,000	$2,000
Pharmacy and product cost (55%)	-$1,100	-$1,100
Contribution before platform fee	$900	$900
Platform fee	Flat per-order buy-down, about $6 per order = -$60	20% of order value = -$400
Lifetime value (contribution)	$840	$500
CAC	$200	$200
LTV:CAC ratio	4.2:1	2.5:1
CAC payback	~2.4 months	~4.0 months

Same patients, same acquisition cost, same retention. The fee model alone moves the clinic from a healthy 4.2:1 to an unscalable 2.5:1, and pushes payback from under two and a half months to four. A 20% order-value tax removed about $340 of lifetime value per patient in this illustration, and it removed more from the clinics with the best retention, because those patients place the most orders.

To be precise about neolife's own economics: neolife is a flat FMV SaaS fee plus a per-order buy-down, and pharmacies pay nothing. That per-order fee is a fixed amount, not a share of order value, which is why it sits in the flat-fee column above and does not scale with your lifetime value as patients refill.

Why the flat structure protects the ratio

Three things fall out of the math:

• The flat fee is roughly constant per order, so as retention rises, the fee stays flat while lifetime value climbs, and the ratio improves.
• The percentage fee rises with both order value and refill count, so it captures a larger slice exactly where your economics are strongest.
• Because the flat fee does not compound with order value, your gross margin per order is more predictable, which we cover alongside category strategy in our work on protecting margins through the model you build for a DTC telehealth brand.

Ownership compounds the effect. When you keep the patient relationship and the storefront, the lifetime value you build accrues to your book, not a platform's, a point we make in owning the patient relationship and its book value. A rail that overlays the pharmacy you already use, rather than inserting itself as a percentage toll, is the structural choice that keeps the ratio on your side.

How should a clinic use these benchmarks in practice?

Use the ratio to decide whether to scale, use payback to decide how fast, and audit your fee structure to make sure neither metric is being taxed by a percentage you do not control. Recompute both quarterly as retention data matures, since early-cohort lifetime value is an estimate until refills actually land.

A practical sequence:

1. Measure real refill retention per cohort rather than assuming a lifetime; early estimates tend to be optimistic.
2. Compute contribution-margin LTV, net of every fee that touches order value, not gross revenue.
3. Divide by fully loaded CAC, including creative, media, intake, and provider review costs.
4. Check payback separately, because a strong ratio can still hide a cash-flow squeeze.
5. Model the ratio under each fee structure you are offered, using the comparison table above as a template.

One honest caveat on the statistics: every dollar figure here is illustrative and chosen to make the mechanics legible. The 3:1 floor and the 4:1 to 6:1 target are widely repeated conventions from software and venture practice, not measured outcomes for your clinic. Your real numbers depend on your category, your retention, and your fee load. The direction of the argument, though, holds across inputs: a percentage of order value is a percentage of your lifetime value, and it moves the benchmark that decides whether you can grow.

A flat-fee rail preserves your unit economics as your patients refill, instead of taxing the retention you worked to build. If you want to pressure-test your LTV:CAC under a flat structure, talk to us.

This article is for informational purposes only and is not legal, medical, financial, or regulatory advice; consult qualified professionals for your specific situation.

Author: neolife editorial desk.